<DOC>
	<DOCNO>NCT01561937</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial evaluate efficacy activate recombinant human factor VII mitigate experimentally-induced bleeding healthy volunteer treat warfarin reach target INR ( International Normalization Ratio ) .</brief_summary>
	<brief_title>Use Activated Recombinant Human Factor VII Reduce Bleeding Caused Warfarin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Warfarin</mesh_term>
	<criteria>INR equal 1.2 The receipt investigational drug within 1 month prior trial Use anticoagulation therapydefined vitamin K antagonist , platelet antagonist , heparin ( low molecular weight heparin ) , aspirin NSAIDs ( NonSteroidal AntiInflammatory Drug ) within 14 day prior trial AfricanAmerican race Weight 160 kg Supplemental Vitamin K use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>